Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

Centocor: Not Yet In Recovery

Inside Wall Street


Although most biotech stocks have been badly beaten up over the past two years, Centocor has managed to stay aloft at around 12, where it has been trading since December. Of late, Centocor seems to have gotten a shot in the arm, which gave analysts reason to raise their estimates. "But watch out," warns investment adviser Evan Sturza. He expects the stock to skid to 7.

Sturza, editor of Sturza's Medical Investment Letter, notes that analysts' renewed optimism was due to the recent vote by a Food & Drug Administration panel to approve Centocor's

ReoPro, an experimental drug to prevent blood clots during coronary angioplasty surgery. Sturza contends that, contrary to some analysts' expectations, the FDA move won't necessarily produce earnings for Centocor, which has been in the red for the past four years. He says that the approval is "limited and conditional" and that Centocor will have to complete further studies to validate its claim on the efficacy of the drug. These costly studies, Sturza says, will prevent Centocor from becoming profitable next year.

According to Sturza, the bulls' estimates that it will make 33 cents to 83 cents a share in 1995 are "just wrong." He notes that Centocor's marketing pact with Eli Lilly stipulates that each gets 50% of Centocor's earnings. So whatever Centocor will make from ReoPro will have to be split with Lilly, anyway, says Sturza, who sees Centocor continuing to post losses. Centocor CEO David Holveck contends, however, that Sturza is way off. Holveck sees Centocor making money next year.GENE G. MARCIAL

blog comments powered by Disqus